Newton Tech is the movement intelligence platform for clinical trials. We turn video of a patient walking — a GRASS assessment, a 10-Meter Walk Test, any gait protocol — into hundreds of objective, quantitative endpoints. No new hardware. No new protocols. Just the data your trial was missing.
Talk to us →A patient walks twenty meters. It takes 14.3 seconds. What does that tell you?
Not enough.
Standard movement assessments have been the backbone of neurological and musculoskeletal trials for decades. The problem isn't the assessments — it's what we do with them. A timestamp is a starting point. Our platform turns it into a clinical picture.
Our platform extracts hundreds of biomechanical markers from the same video — stride variability, ground contact asymmetry, trunk stability, movement quality, and more — turning one standard assessment into a multidimensional clinical picture. No new hardware. No new protocols. No changes to your study design.
That depth changes what's possible. When a patient improves on a timed walk test, the question that matters most is: why did they improve? Was it the drug — or were they compensating? True mechanistic recovery and adaptive movement look identical on a stopwatch. They don't look identical to our platform.
The worst outcome in a clinical trial isn't a null result — it's a confounded one. A patient who improves on a timed walk could be recovering neurologically, or compensating mechanically. Those aren't the same mechanism. Treating them as equivalent is how trials misread their own data — and how efficacy signals get reported that don't hold up.
Our platform distinguishes true mechanistic recovery from compensatory movement, from the same video, the same protocol, no additional instrumentation. It's the difference between a finding that changes the science and one that later has to be walked back. For trials at a critical readout, that distinction isn't academic. It's the difference between a program that continues and one that doesn't.
We work with pharmaceutical companies and CROs running trials where movement is an endpoint — including MS, ALS, Parkinson's, SCI, stroke, TBI, and rare neuromuscular disease. If your trial captures a gait or movement assessment, our platform turns it into a richer clinical signal.
For teams not yet using a standardized movement assessment, we help identify the right protocol and integrate quantitative endpoints into an existing study design without disruption.
Movement is one of the most information-dense biological signals in the human body. Decades of peer-reviewed literature have established gait, posture, and movement dynamics as sensitive markers of neurological function, metabolic health, musculoskeletal integrity, and biological aging — often detectable before clinical symptoms emerge.
Our research demonstrates what a single two-minute walk actually contains.
These findings come from video-based analysis alone — no wearables, no sensors, no additional instrumentation. They represent the most comprehensive characterization of movement as a multi-system health signal published to date.
Developed in scientific collaboration with the Weizmann Institute of Science.
Submitted to Nature Medicine, 2025.
Whether you're designing a new trial or looking to get more out of an existing assessment, we'd like to hear about your program.
Talk to us →